Newsroom 2006

2006 Releases

14/12/2006
CSL Limited enters into License and Option Agreement with Wyeth for its Iscomatrix® Adjuvant Technology
CSL Limited, Australia’s leading biopharmaceutical company, today announced that it has signed a worldwide license and option agreement with Wyeth (NYSE: WYE), granting certain rights and options to Wyeth for the use of CSL’s ISCOMATRIX® adjuvant in a number of Wyeth’s investigational vaccine programs. More.

13/12/2006
Strong Trading Conditions in International Plasma Therapies
CSL Limited today lifted its financial guidance for the 2006/2007 financial year following strong trading conditions in the international plasma therapies market. More.

29/11/2006
Australia Poised to Vaccinate a Generation of Women
CSL Limited welcomes today’s announcement by the Prime Minister and the Minister for Health that the Commonwealth Government will make GARDASIL®, the world’s first cervical cancer vaccine, available for school girls aged 12 to 18 years under the Government-funded National Immunisation Program (NIP). In addition, a free vaccine program for women aged 19 -26 will be delivered by General Practitioners. In total, over 1 million Australian women and girls will be covered by the program. More.

09/11/2006
CSL announces acquisition of CytoGam® from MedImmune
Melbourne, Australia: - CSL Limited has announced that its subsidiary, ZLB Behring, has reached an agreement with MedImmune, Inc. to acquire CytoGam®, (cytomegalovirus immune globulin intravenous (human)) and related assets. CytoGam is an intravenous immune globulin enriched in antibodies against cytomegalovirus (CMV), which is indicated for prophylaxis against CMV disease associated with transplantation of the kidney, lung, liver, pancreas and heart. CMV is the most common cause of infection occurring after any solid organ transplant, contributing significantly to morbidity and mortality in organ
transplant recipients. More.

08/11/2006
Cervical cancer vaccination funding for Australian girls rejected
CSL Limited, Australia’s leading biopharmaceutical company, today announced that at last week’s meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) rejected CSL’s funding application for its cervical cancer vaccine GARDASIL®.CSL Limited, Australia’s leading biopharmaceutical company, today announced that at last week’s meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) rejected CSL’s funding application for its cervical cancer vaccine GARDASIL®. More.

01/09/2006
CSL Appoints New Director
CSL today announced that Mr David Simpson has been appointed a Director of the Company effective from 1 September 2006. More.

23/08/2006
CSL Full-year Result Announcement for 2006
CSL Limited today announced its operating result for the full year ended 30 June 2006. More.

23/08/2006
Iconic Australian Company Adopts New Look as a Global Organisation
CSL Limited, Australia’s leading biopharmaceutical company, today announced an updated look with a new logo to bring together its Australian and offshore group of companies together as a single global entity. More.

17/07/2006
CSL Announces Signing of a Merger Implementation Deed to Acquire Zenyth Therapeutics Limited (Zenyth)
CSL Limited (CSL) and Melbourne-based biotech company, Zenyth Therapeutics Limited (Zenyth), today announced a proposal under which CSL would acquire 100% of the issued shares in Zenyth. The acquisition is to be implemented by way of a scheme of arrangement between Zenyth and its shareholders (Share Scheme). More.

26/06/2006
CSL Announces Licence to Market and Distribute Dermatology Range from Intendis GmbH
German-based company, Intendis GmbH (a subsidiary of Schering AG) has granted CSL Limited an exclusive license to market and distribute three of their better known products in Australia. More.

21/06/2006
CSL Makes Provision for Final Payment
CSL Limited today announced that positive business performance has underpinned a decision to make a provision in recognition of the contingent payment(1) arising from the acquisition of Aventis Behring. More.

09/06/2006
CSL Limited Announces FDA Approval of its Licensee Merck & Co Inc's Cervical Cancer Vaccine GARDASIL®
CSL Limited today announced that its licensee, Merck & Co., Inc., has received approval from the U.S. Food and Drug Administration (FDA) of its cervical cancer vaccine GARDASIL® for vaccination of girls and women between the ages 9 and 26. More.

22/02/2006
CSL Limited today announced its first half result for period ended 31 December 2005
CSL Limited today announced its first half result for period ended 31 December 2005 and forecast a profit upgrade for the full year result. More.

08/02/2006
CSL Limited to Apply for License to Market Influenza Vaccine in the U.S.
CSL Limited (ASX: CSL), Australia’s leading biopharmaceutical company today announced plans to introduce its influenza vaccine into the U.S. market. More.

© 2016 CSL Limited